For the year ending 2025-12-31, XLO made $43,766K in revenue. -$35,036K in net income. Net profit margin of -80.05%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 43,766 | |||
| Research and development | 56,039 | |||
| General and administrative | 29,709 | |||
| Total operating expenses | 85,748 | |||
| Loss from operations | -41,982 | |||
| Change in fair value of common stock warrant liabilities | -5,845 | |||
| Other income, net | 1,101 | |||
| Total other income, net | 6,946 | |||
| Net loss and comprehensive loss | -35,036 | |||
| Basic EPS | -4.19 | |||
| Diluted EPS | -4.19 | |||
| Basic Average Shares | 8,359,109 | |||
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)